AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lowered its position in AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 16.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,773 shares of the medical device company’s stock after selling 9,758 shares during the period. Envestnet Asset Management Inc. owned about 0.11% of AtriCure worth $2,253,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in AtriCure by 47.7% in the first quarter. PNC Financial Services Group Inc. now owns 5,975 shares of the medical device company’s stock valued at $392,000 after acquiring an additional 1,931 shares during the period. AlphaCrest Capital Management LLC acquired a new stake in shares of AtriCure during the 1st quarter valued at approximately $343,000. MetLife Investment Management LLC lifted its position in shares of AtriCure by 54.8% during the 1st quarter. MetLife Investment Management LLC now owns 24,141 shares of the medical device company’s stock valued at $1,585,000 after acquiring an additional 8,549 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of AtriCure by 7.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 717,125 shares of the medical device company’s stock valued at $47,092,000 after acquiring an additional 46,705 shares during the period. Finally, Sei Investments Co. lifted its position in shares of AtriCure by 0.5% during the 1st quarter. Sei Investments Co. now owns 94,103 shares of the medical device company’s stock valued at $6,182,000 after acquiring an additional 461 shares during the period. Institutional investors and hedge funds own 95.27% of the company’s stock.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $48.29 on Friday. AtriCure, Inc. has a fifty-two week low of $32.51 and a fifty-two week high of $52.96. The business has a 50 day moving average price of $42.97 and a two-hundred day moving average price of $42.91. The company has a quick ratio of 3.03, a current ratio of 3.82 and a debt-to-equity ratio of 0.13. The firm has a market cap of $2.28 billion, a PE ratio of -58.89 and a beta of 1.35.

AtriCure (NASDAQ:ATRC – Get Rating) last announced its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.11. The company had revenue of $93.49 million during the quarter, compared to analyst estimates of $87.53 million. AtriCure had a negative net margin of 10.81% and a negative return on equity of 9.18%. The firm’s revenue for the quarter was up 25.4% compared to the same quarter last year. During the same period last year, the business earned ($0.33) EPS. Sell-side analysts expect that AtriCure, Inc. will post -1.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on ATRC. StockNews.com began coverage on shares of AtriCure in a research note on Thursday. They issued a “hold” rating on the stock. Canaccord Genuity Group dropped their price target on shares of AtriCure from $81.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, February 22nd. Needham & Company LLC upped their price target on shares of AtriCure from $58.00 to $60.00 in a research report on Wednesday, May 3rd. Stifel Nicolaus upped their price target on AtriCure from $48.00 to $50.00 in a research note on Wednesday, May 3rd. Finally, BTIG Research dropped their price target on AtriCure from $65.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, February 22nd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.83.

AtriCure Profile

(Get Rating)

AtriCure, Inc engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration.